International Journal of Peptide Research and Therapeutics (May 2026): Peptide-Based Cancer Vaccines Review — Engineering Immune Precision Against Tumor Evolution
A review article published in the International Journal of Peptide Research and Therapeutics in May 2026 consolidates the current state of peptide-based cancer vaccines, covering antigen selection, adjuvant chemistry, and delivery platforms designed to address tumor evolution and immune escape. The review argues that despite persistent challenges around peptide stability and limited immunogenicity, the combination of nanomaterials and adjuvants has significantly enhanced immune response efficiency and targeted delivery — with applications in drug-resistant and metastatic cancers. The piece sits alongside two other May peptide vaccine reviews (WIRES Nanomedicine, Science Advances) and frames the ASCO 2026 peptide-oncology slate (BioVaxys MVP-S, BriaCell Bria-IMT, Evaxion EVX-01) as the clinical pipeline backing the review-paper momentum.